Vascular Endothelial Growth Factor is Associated with the Efficacy of Endocrine Therapy in Patients with Advanced Breast Carcinoma

Cancer

Volumn 98, Issue 10, 2003, Pages 2125-2132

  Manders, Peggy ^a   Beex, Louk V A M ^a   Tjan Heijnen, Vivianne C G ^a   Span, Paul N ^a   Sweep, C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced breast cancer; Angiogenesis; Chemotherapy; Endocrine therapy; Predictive; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE; MEDROXYPROGESTERONE; METHOTREXATE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; TISSUE LEVEL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0242611595     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11764     Document Type: Article

References (25)

1. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast (2nd edition). Philadelphia: Lippincott Williams & Wilkins, 2000:749-797.
2. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133-146.
3. Dickson RB, Lippman ME. Cancer of the breast: Management of metastatic disease. In: DeVita VF Jr., Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology (5th edition). Philadelphia: Lippincott-Raven, 2000:1602-1606.
4. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988; 15:20-25.
5. McGuire WL, Clark G. Role of progesterone receptors in breast cancer. Semin Oncol. 1985;12:12-16.
6. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med. 1988;109:219-228.
7. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227-238.
8. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res. 2003;9:460S-467S.
9. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-2356.
10. Sjöström J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol. 2002;41:334-345.
11. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
13. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma. J Natl Cancer Inst. 1997;89:139-147.
14. Coradini D, Boracchi P, Daidone MG, et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer. 2001;85:795-797.
15. Gasparini G, Toi M, Biganzoli E, et al. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology. 2001;60:72-80.
16. Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer. 2002;87:772-778.
17. Gasparini G, Toi M, Miceli R, et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am. 1999;5:101-111.
18. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000;18:1423-1431.
19. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61:5407-5414.
20. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM, Sweep CG. EORTC Receptor and Biomarker Study Group report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers. 2000;15: 184-191.
21. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Knight WA III, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980;9:361-368.
24. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884-2888.
25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.